Castle Biosciences, Inc., has announced the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a price to the public of US$37.00 per share. The gross proceeds to Castle Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be US$74.0 million. In addition, Castle Biosciences has granted the underwriters a 30-day option to purchase up to an additional 300,000 shares of common stock at the offering price, less the underwriting discounts and commissions.
Latham & Watkins LLP represents Castle Biosciences, Inc. in the public offering with a capital markets team led by partners Peter Handrinos and Wesley Holmes, with associates Anthony Gostanian and Kiara Vaughn.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.